STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will report its first quarter 2024 financial results and provide a business update on May 9, 2024. Altimmune management will host a conference call to discuss the financial results and business update.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+1.70% News Effect

On the day this news was published, ALT gained 1.70%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
reisenstadt@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com


FAQ

When will Altimmune report its first quarter 2024 financial results?

Altimmune will report its first quarter 2024 financial results on May 9, 2024.

Where can I listen to the conference call discussing Altimmune's financial results?

The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

How can I join the conference call?

Participants can register on Altimmune's website to receive the dial-in numbers and unique PIN to access the call.

Will there be a replay of the conference call available?

Yes, a replay will be available on the Investor Relations website for up to three months after the call.
Altimmune

NASDAQ:ALT

ALT Rankings

ALT Latest News

ALT Latest SEC Filings

ALT Stock Data

566.58M
103.60M
0.78%
43.32%
30.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
GAITHERSBURG